Preimplantation Genetic Testing Market Size by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028
The global size of preimplantation genetic testing market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
The growth in this market is attributed to the increasing demand for assisted reproductive technologies, rising maternal age trends, and ongoing research and development in the field of genetics. On the other hand, socio-ethical concerns surrounding preimplantation genetic testing may challenge the growth of market. Whereas, use of fertility treatment options by single parents and same-sex couples provides growth opportunities for market.
Attractive Opportunities in the Preimplantation Genetic Testing Market
To know about the assumptions considered for the study, Request for Free Sample Report
Preimplantation Genetic Testing Dynamics
DRIVER: Declining fertility rate
Global fertility rates are observing a decline across a majority of the developed and several developing countries, owing to various factors such as increased maternal age of conceiving, low sperm count & motility, and hormonal imbalance, thereby leading to higher demand for IVF procedures. Moreover, with growing public awareness about the effective role of genetic techniques in the risk assessment of genetic disorders, the adoption of preimplantation genetic testing procedures is expected to grow during the forecast period. According to the World Health Organization (WHO), in 2020, approximately 8 million couples and 186 million individuals lived with infertility.
RESTRAINT: Alternative therapies and medications
The preimplantation genetic testing market is highly regulated, especially across the developed countries. For instance, in the U.S., service providers offering preimplantation genetic diagnosis & preimplantation genetic screening in IVF treatment have to adhere to mandatory regulations. Moreover, due to socio-ethical concerns related to embryo testing, a number of governments across the world are implementing stringent regulations, which is expected to negatively impact the growth of the preimplantation genetic diagnosis & preimplantation genetic screening market.
OPPORTUNITY: Use of fertility treatment options by single parents and same-sex couples
Regulations legalizing same-sex marriages in various countries across the globe, including Greenland, Ireland, Canada, South Africa, and the US, are further expected to increase the adoption of fertility procedures. The laws that support the use of IVF procedures by same-sex and single parents are as follows such as The New South Wales Assisted Reproductive Technology Act 2007 permits all women, regardless of marital status, to access assisted conception procedures in the Australian state. On the other hand The Human Reproductive Technology Act 1991 allows all women (lesbian or single) to access donor insemination in Western Australia.
CHALLENGE: Socio-ethical concerns surrounding preimplantation genetic testing
Issues related to embryos and what to do with unused embryos are one of the major concerns related to the preimplantation genetic testing procedure. A number of couples fertilize as many eggs as they can during the treatment and freeze the remaining embryos for later use. Once the procedure is complete, several embryos remain unused, and clinics are reluctant to dispose of these unused embryos without the couples’ consent.
Preimplantation Genetic Testing Ecosystem
Prominent companies in this market include well-established, financially stable manufacturers of diagnostic and therapeutic preimplantation genetic testing. These companies have been operating in the market for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in this market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US).
In 2022, reagents and consumables to observe highest growth rate of the preimplantation genetic testing industry, by product.
Based on the products, the global preimplantation genetic testing market is broadly segmented into instruments, reagents & consumables, and software & services. The expanding applications of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders) and increasing number of preimplantation genetic diagnosis & preimplantation genetic screening procedures being performed across the world’s major markets are driving the growth of the reagents and consumables segment.
In 2022, fertility centers segment to dominate the preimplantation genetic testing industry, by end user.
Based on end users, the preimplantation genetic testing market is segmented into hospitals, diagnostic labs, fertility clinics, and other end users. With declining fertility rates and the subsequent growth in the number of fertility centers, the number of infertility treatment procedures drives the demand for fertility centers market.
In 2022, North America to dominate in preimplantation genetic testing industry.
The global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America is expected to dominate during the forecast period, primarily due to the rising prevalence of polycystic ovary syndrome (PCOS), growing incidence of reproductive diseases such as chlamydia, and increasing age of first-time pregnancy.
To know about the assumptions considered for the study, download the pdf brochure
The preimplantation genetic testing market is dominated by players such Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US).
Scope of the Preimplantation Genetic Testing Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$0.7 billion |
|
Estimated Value by 2028 |
$1.2 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 11.4% |
|
Market Driver |
Declining fertility rate |
|
Market Opportunity |
Use of fertility treatment options by single parents and same-sex couples |
This research report categorizes the Preimplantation genetic testing market to forecast revenue and analyze trends in each of the following submarkets:
By Region
- North America
- Europe
- Asia Pacific
- Rest of the World
By Procedure Type
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
By Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence In Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
By Product
- Reagents and Consumables
- Instruments
- Software and Services
By Application
- Aneuploidy
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-Linked Disorders
- HLA Typing
- Gender Identification
By Type of Cycle
- Fresh Non-Donor
- Frozen Non-Donor
- Fresh Donor
- Frozen Donor
By End User
- Fertility Clinics
- Hospitals
- Diagnostic Laboratories
- Other End Users
Recent Developments of Preimplantation Genetic Testing Industry
- In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
- In 2022, The Cooper Companies, Inc. (US) released the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
- In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services primarily for IVF clinics.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global preimplantation genetic testing market?
The global preimplantation genetic testing market boasts a total revenue value of $1.2 billion by 2028.
What is the estimated growth rate (CAGR) of the global preimplantation genetic testing market?
The global preimplantation genetic testing market has an estimated compound annual growth rate (CAGR) of 11.4% and a revenue size in the region of $0.7 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements and partnerships of the leading players, the competitive landscape of the preimplantation genetic testing market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Collecting Secondary Data
The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the preimplantation genetic testing market. A database of the key industry leaders was also prepared using secondary research.
Collecting Primary Data
The primary research data was collected after acquiring knowledge about the preimplantation genetic testing market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as fertility clinics, maternity centers, diagnostic laboratories, hospitals, and academic & research institutes) and supply-side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, and Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:
Breakdown of Primary Participants:
Note 1: *Others include sales managers, marketing managers, and product managers.
Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Illumina, Inc. |
General Manager |
|
VitroLife |
Senior Product Manager |
|
Agilent Technologies, Inc. |
Regional Manager |
|
Thermo Fisher Scientific, Inc. |
General Manager of Sales |
Market Size Estimation
All major product manufacturers offering various preimplantation genetic testing products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value preimplantation genetic testing market was also split into various segments and subsegments at the region and country level based on:
- Product mapping of various manufacturers for each type of preimplantation genetic testing market at the regional and country-level
- Relative adoption pattern of each preimplantation genetic testing market among key application segments at the regional and/or country-level
- Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
- Detailed secondary research to gauge the prevailing market trends at the regional and/or country level
Global Preimplantation Genetic Testing Market Size: Botton Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global Preimplantation Genetic Testing Market Size: Top Down Approach
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Preimplantation genetic testing industry.
Market Definition
Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman’s uterus for a range of genetic problems that can cause implantation failure, miscarriage and birth defects in a resulting child. Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:
- Preimplantation genetic screening for abnormal chromosome number (PGT-A)
- Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
- Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.
Key Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global preimplantation genetic testing market by procedure type, technology, product, application, type of cycle, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World.
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence.
Available Customizations
MarketsandMarkets offers the following customizations for this market report:
- Additional country-level analysis of the Preimplantation genetic testing market
- Profiling of additional market players (up to 5)
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the Preimplantation genetic testing Market
Generating Response ...
Growth opportunities and latent adjacency in Preimplantation Genetic Testing Market